CJC-1295 + Ipamorelin blend is a single-vial co-formulation pairing the short-acting GHRH analogue CJC-1295 No DAC with the selective growth hormone secretagogue ipamorelin. The combination engages two distinct receptors in the GH-secretion axis simultaneously.
Definition
The CJC-1295 + Ipamorelin blend combines two peptides at fixed proportions in a single lyophilised vial: CJC-1295 No DAC (5 mg) plus ipamorelin (5 mg). Each component compound is also available standalone from the Ronin catalog; the blend format pairs them at convenient working concentrations for combined-research workflows. The two components engage two non-overlapping receptors in the growth hormone release axis: CJC-1295 No DAC at the GHRH receptor on pituitary somatotrophs, and ipamorelin at the growth hormone secretagogue receptor (GHSR-1a, the ghrelin receptor) on the same somatotroph population and adjacent endocrine cell types.
The mechanistic rationale for the combination is that GHRH-receptor agonism and ghrelin-receptor agonism produce additive (and possibly synergistic) effects on GH release because the two pathways converge on the same somatotroph but engage independent G-protein-coupled receptor cascades. The CJC-1295 arm provides sustained GHRH-receptor stimulation; the ipamorelin arm provides selective ghrelin-receptor activation without the cortisol, prolactin, or ACTH elevation seen with earlier-generation GH secretagogues.
How the combination is used in research workflows
The blend is supplied as a lyophilised vial reconstituted with bacteriostatic water at the bench. A standard 10 mg vial reconstituted with 2 mL of bacteriostatic water yields CJC-1295 No DAC at 2.5 mg/mL and ipamorelin at 2.5 mg/mL simultaneously. The blend format removes the need to reconstitute two separate vials and combine them at the bench; researchers who prefer to control the component concentrations independently can use the standalone single-compound vials for each instead.
The published research literature on the combination specifically is limited; the great majority of the published GH-secretagogue and GHRH-analogue work focuses on the individual components. The combined-mechanism rationale derives from independent characterisation of each component (CJC-1295 in PMID 15817669, PMID 16352683, PMID 16822960, PMID 17018654, PMID 19386527; ipamorelin in PMID 9849822, PMID 19289567, PMID 25331030).
Related terms
- CJC-1295 No DAC
- Ipamorelin
- Growth hormone receptor (downstream of pituitary GH release)
- GHRH receptor (the CJC-1295 target)
- GHSR-1a / ghrelin receptor (the ipamorelin target)
- Somatotroph
Where the blend appears in the Ronin catalog
- CJC-1295 + Ipamorelin blend 10mg — single-vial co-formulation
- CJC-1295 No DAC 10mg — single-component standalone vial
- Ipamorelin 10mg — single-component standalone vial
References
- Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998;139(5):552-561. [PMID 9849822]
- Jetté L et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology 2005;146(7):3052-3058. [PMID 15817669]
- Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab 2006;91(3):799-805. [PMID 16352683]
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab 2006;91(12):4792-4797. [PMID 17018654]
Glossary entries describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. The CJC-1295 + Ipamorelin blend is sold strictly as a research-grade reagent for laboratory and bench research applications.